Valuation: Roche Holding AG

Capitalization 273B 350B 302B 262B 477B 32,194B 499B 3,223B 1,291B 15,439B 1,315B 1,287B 55,216B P/E ratio 2026 *
18.2x
P/E ratio 2027 * 16.8x
Enterprise value 281B 361B 311B 270B 492B 33,187B 515B 3,323B 1,331B 15,915B 1,355B 1,326B 56,919B EV / Sales 2026 *
4.48x
EV / Sales 2027 * 4.2x
Free-Float
87.84%
Yield 2026 *
2.95%
Yield 2027 * 3.03%
1 day-2.93%
1 week-7.03%
Current month-7.03%
1 month-4.26%
3 months+9.75%
6 months+24.43%
Current year+3.96%
1 week 339.3
Extreme 339.3
365.3
1 month 339.3
Extreme 339.3
374.9
Current year 323.2
Extreme 323.2
374.9
1 year 231.9
Extreme 231.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Tech/Sci/R&D Officer 59 2025-02-09
Director TitleAgeSince
Director/Board Member 67 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5d. change 1-year change 3-years change Capi.($)
-2.93%-7.03%+12.72%+26.04% 350B
+0.72%-5.86%+8.50%+210.49% 885B
+0.32%-3.23%+44.97%+54.54% 579B
-0.96%-0.85%+9.19%+48.19% 407B
-1.25%-5.55%+23.92%+55.59% 302B
-1.85%-6.70%+20.55%+34.98% 301B
-0.24%-6.49%+23.18%+4.22% 286B
+0.53%-4.80%+16.27%+57.17% 199B
-0.83%-3.37%+24.03%+77.45% 179B
-0.30%+4.20%-59.52%-50.81% 171B
Average -0.68%-3.80%+12.38%+51.79% 365.97B
Weighted average by Cap. -0.46%-4.18%+16.17%+79.69%

Financials

2026 *2027 *
Net sales 62.72B 80.59B 69.48B 60.18B 110B 7,406B 115B 741B 297B 3,552B 302B 296B 12,702B 65.29B 83.89B 72.33B 62.65B 114B 7,709B 120B 772B 309B 3,697B 315B 308B 13,222B
Net income 14.67B 18.85B 16.25B 14.08B 25.67B 1,732B 26.86B 173B 69.47B 831B 70.73B 69.23B 2,971B 15.85B 20.36B 17.56B 15.21B 27.73B 1,871B 29.02B 187B 75.05B 897B 76.42B 74.79B 3,209B
Net Debt 8.41B 10.8B 9.31B 8.07B 14.71B 993B 15.4B 99.39B 39.82B 476B 40.54B 39.68B 1,703B 1.29B 1.66B 1.43B 1.24B 2.26B 152B 2.36B 15.24B 6.1B 72.99B 6.22B 6.08B 261B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-03-06 341.20 CHF -2.93% 1,339,562
26-03-05 351.50 CHF -2.03% 1,087,503
26-03-04 358.80 CHF +0.96% 961,103
26-03-03 355.40 CHF -2.07% 1,236,547
26-03-02 362.90 CHF -1.12% 1,392,158
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
341.20CHF
Average target price
360.74CHF
Spread / Average Target
+5.73%

Quarterly revenue - Rate of surprise